ehealth presentation at ens-efn istanbul
DESCRIPTION
eHealthTRANSCRIPT
![Page 1: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/1.jpg)
eHealth: Improving patient engagement Gavin Giovannoni
![Page 2: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/2.jpg)
• Serves on scientific advisory boards for Merck Serono, Biogen Idec and Vertex Pharmaceuticals; and on the speakers bureau for Merck Serono
• Has received speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sanofi-Aventis, Vertex Pharmaceuticals, Genzyme Corporation, Ironwood and Novartis
• Has served as a consultant for Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd, Sanofi-Aventis, UCB, Vertex Pharmaceuticals, GW Pharma, Novartis and FivePrime
• Has received research support unrelated to this study from Biogen Idec, Merck Serono, Novartis and Ironwood
Disclosures
![Page 3: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/3.jpg)
Topics to be covered
1. What is eHealth?
2. Patient education
3. Communication
4. Data exchange
5. Patient engagement
6. Trends in eHealth
![Page 4: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/4.jpg)
“eHealth is a form of healthcare practice supported by electronic processes and communication”
The broad definition includes health informatics and a more restricted or narrow definition refers to healthcare practice using the internet and health applications, and links on mobile phones (mHealth)
What is eHealth?
Della Mea V. J Med Internet Res 2001;3:e22
![Page 5: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/5.jpg)
1. Yes
2. No
3. Don’t know
Do you think using eHealth (e.g. internet-linked devices, online tools and information, social media) could increase your patients’ engagement?
Voting pad question
![Page 6: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/6.jpg)
Why am I involved in eHealth?
![Page 7: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/7.jpg)
Time is my most precious resource?
NHS, National Health Service
Prof Giovannoni is working hard for you!
Overbooked, harassed
8 new & 20 follow-up slots per clinic
Double-bookings
Running between consulting rooms A & B
The 5-min history & 5-min neurological examination
The NHS is working hard for you!
![Page 8: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/8.jpg)
Time Repetition
![Page 9: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/9.jpg)
Why speak to the individual when you can have a dialogue with several patients at once?
Why repeat yourself?
![Page 10: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/10.jpg)
eHealth is potentially the key to the world
![Page 11: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/11.jpg)
42-year-old male, diagnosed with RRMS aged 32 years
• Interferon-beta for 8 years
• Relapse free for at least 4 years
• Last 2 years, noticed increasing difficulty walking; now using a walking stick
Question: “Professor Giovannoni, have you heard about liberation therapy? Would you recommend venoplasty?”
Case study 1, 2, 3, 4, …n
RRMS, relapsing–remitting MS
![Page 12: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/12.jpg)
![Page 13: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/13.jpg)
CCSVI, chronic cerebrospinal venous insufficiency
![Page 14: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/14.jpg)
A blog for people with MS and their families: “Interpreting the good, bad and other research news”
[Name removed]
![Page 15: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/15.jpg)
My beloved country
"There is a lovely road that runs from Ixopo into the hills..."
Paton A. Cry, the Beloved Country, Chapter 1; Oprah's Book Club Edition. Scribner. 2003 HIV, human immunodeficiency virus
![Page 16: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/16.jpg)
Guardian website. November 2008
![Page 17: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/17.jpg)
Four types of AIDS denialist:
1. The ‘dissident scientist’ who lends credibility
2. The ‘cultropreneur’ who peddles quack therapies
3. The ‘living icon’ or ‘long-term survivor’
4. The ‘praise-singer’, ‘journalist’ or ‘politician’ who sows doubt about HIV causing AIDS
The HIV/AIDS community
1. Patient activists/organisers
2. Access to media
3. Conspiracy theories
HIV/AIDS analogy
HIV/AIDS, human immunodeficiency virus/ acquired immunodeficiency syndrome Nattrass N. The AIDS Conspiracy: Science Fights Back. © Columbia University Press. 2012
![Page 18: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/18.jpg)
CCSVI
CCSVI, chronic cerebrospinal venous insufficiency
![Page 19: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/19.jpg)
Gafson AR, Giovannoni G. Mult Scler Relat Disord 2014;3:143-6
![Page 20: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/20.jpg)
Clinical practice?
![Page 21: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/21.jpg)
Question: “Professor Giovannoni, I have had relapsing–remitting MS for 7 years; 4.5 years on interferon-beta until pregnancy, no medication for 2.5 years, mild symptoms once a year. I have been offered glatiramer acetate injection by my consultant. Should I start this?”
Case study
![Page 22: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/22.jpg)
Clinic speak
Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. July 2013
![Page 23: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/23.jpg)
Question: “Professor Giovannoni, I have had 33 natalizumab infusions and I have just found out that I am JC virus seropositive with an antibody index of 3.2. What should I do?”
Case study
![Page 24: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/24.jpg)
PML
PML, progressive multifocal leukoencephalopathy Barts and The London NHS Trust. Natalizumab Information Sheet. July 2010
![Page 25: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/25.jpg)
Survey: Natalizumab and its complications
From SurveyMonkey™
![Page 26: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/26.jpg)
Barts and The London NHS Trust. Natalizumab Information Sheet. July 2010
![Page 27: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/27.jpg)
![Page 28: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/28.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 29: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/29.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 30: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/30.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 31: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/31.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 32: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/32.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 33: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/33.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 34: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/34.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 35: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/35.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 36: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/36.jpg)
17% 85%
![Page 37: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/37.jpg)
Barts and the London School of Medicine and Dentistry. PML Risk Education Guide. 2013
![Page 38: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/38.jpg)
Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. April 2014
![Page 39: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/39.jpg)
http://www.slideshare.net/gavingiovannoni/barts-the-london-pml-risk-education-guide-june-2013
![Page 40: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/40.jpg)
Question: “Professor Giovannoni, I have had 33 natalizumab infusions and I have just found out that I am JC virus seropositive with an antibody index of 3.2. What should I do?”
Other case studies
![Page 41: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/41.jpg)
Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. May 2013
![Page 42: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/42.jpg)
Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. August 2013
![Page 43: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/43.jpg)
![Page 44: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/44.jpg)
Epstein–Barr virus
Genetics
Vitamin D
Smoking
Risks
Adverse events
Differential diagnosis
MRI
Evoked potentials
Lumbar puncture
Blood tests
Diagnostic criteria
Cognition
Depression
Fatigue
Bladder
Bowel
Sexual dysfunction Tremor
Pain Swallowing
Spasticity Falls
Balance problems Insomnia
Restless legs Fertility
Clinical trials
Gait
Pressure sores
Oscillopsia
Emotional lability
Seizures
Gastrostomy
Rehab
Suprapubic catheter Intrathecal
baclofen
Physio- therapy
Speech therapy
Occupational therapy
Functional neurosurgery
Colostomy
Tendonotomy
Studying
Employment Relationships
Travel
Vaccination
Anxiety
Driving
Nurse specialists
Family counselling
Relapses
1st line
2nd line
Maintenance Escalation Induction
Monitoring
Disease-free
Disease progression
DMTs
Side effects
Advanced directive
Exercise
Diet
Alternative medicine
Pregnancy Breast feeding
Research
Insurance
Visual loss
Palliative care
Assisted suicide
Social services
Legal aid
Genetic counselling
Prevention
Diagnosis
DMT
Symptomatic
Therapist
Terminal
Counselling A holistic approach to MS
Intrathecal phenol
Fractures
Movement disorders
Osteopaenia
Brain atrophy
Hearing loss
Tinnitus
Photophobia
Hiccoughs
DVLA
Neuroprotection
Psychosis
Depersonalization
Brain health
Cognitive reserve
Sudden death
Suicide
OCD
Narcolepsy
Apnoea
Carers
Respite
Hospice
Respite
Dignitas
Advanced directive
Rhizotomy
Rhizotomy
Wheelchair
Walking aids
Blood/organ donation
Brain donation
Exercise therapy
NAbs
Autoimmunity
Infections
Outcome measures
Web resources
Pathogenesis
Double vision
What is MS?
NEDA
T2T OCT
Neurofilaments
JCV status Pharma
Anaesthesia
![Page 45: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/45.jpg)
Monitoring your own disease
Patientslikeme®. April 2014
![Page 46: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/46.jpg)
HealthVault. April 2014
![Page 47: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/47.jpg)
Normal neurological examination
No disability
Minimal disability
Moderate disability
Relatively severe
disability
Disability precludes full daily activities
Assistance required to walk
Restricted to a
wheelchair
Restricted to bed
or chair
Confined to bed
Death
0.0 1.0
2.0 3.0 4.0
5.0 6.0
7.0 8.0
9.0 10.0
![Page 48: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/48.jpg)
Leddy S et al. J Neurol 2013;260:2505-10. Copyright © 2013, Springer-Verlag Berlin Heidelberg
Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis
* * *
* *
* * *
*
*
*
*
*
* *
*
* *
*
*
*
*
* *
*
*
*
*
4
3
2
0
1
–1
–2
–3
–4
0 1 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.5 6.0 6.5 7 8
P-EDSS
Web
- ED
SS-
P-E
DSS
* *
EDSS, Expanded Disability Status Scale
![Page 49: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/49.jpg)
• eHealth – currently in the early stages of development
• Government legislation is driving organizations to look to eHealth as a healthcare model
• Organizations believe the greatest benefits of eHealth involve increased efficiency and enhanced ability of healthcare providers to deliver safe and effective care
• Data security is the number one eHealth issue concerning organizations
• Government agencies, health departments and provider organizations are the major solution drivers for eHealth
Trends in eHealth
http://www.wipro.com/Documents/resource-center/library/eHealth.pdf
![Page 50: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/50.jpg)
1. Information resources
2. Risk assessment tools
3. Patient discussion groups, social media, blogs
4. Interactive services to track disease outcomes, quality of life, etc
5. Adherence-logging devices and phone reminder services
What aspects of eHealth do you think could be of most benefit to your patients?
Voting pad question
![Page 51: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/51.jpg)
Adapt or die?
![Page 52: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/52.jpg)
Analogue or digital?
Dinosaur or wired?
![Page 53: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/53.jpg)
Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. February 2014
![Page 54: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/54.jpg)
![Page 55: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/55.jpg)
• eHealth is here to stay (you can either adapt or die)
• Adoption is occurring very rapidly in some sectors
• Advantages are obvious
– Improved efficiency (cost and time effective)
– Better outcomes
– Higher satisfaction
• Hurdles to adoption are not insurmountable
– Privacy and data protection
– Medico-legal issues
Conclusions
![Page 56: eHealth presentation at ENS-EFN Istanbul](https://reader034.vdocuments.mx/reader034/viewer/2022042623/54635882b4af9f581c8b4be5/html5/thumbnails/56.jpg)
Q&A
Don’t forget to complete your evaluation forms